John D Imig1. 1. Vascular Biology Center, Medical College of Georgia, Augusta, GA 30912, USA. jdimig@mcg.edu
Abstract
BACKGROUND: Obesity, hypertension and Type 2 diabetes are major contributing factors to the increase in the number of patients that have chronic kidney disease. The clustering of visceral obesity and cardiovascular risk factors has been designated metabolic syndrome or cardiometabolic syndrome. Cardiometabolic syndrome is associated with a complex systemic inflammatory state that has been implicated in medically important complications, including endothelial dysfunction. Inflammation, endothelial dysfunction and insulin resistance are interrelated and have reciprocal relationships that link cardiovascular and metabolic diseases. Ultimately, cardiometabolic syndrome increases the risk for cardiovascular events and end-organ damage. Although the number of patients with cardiometabolic syndrome is escalating, therapeutic approaches have not been developed that provide protection to the kidney. OBJECTIVE: The objective of this review is to provide an overview of the contribution of eicosanoids to renal damage in cardiometabolic syndrome. RESULTS/ CONCLUSION: Eicosanoids are altered in cardiometabolic syndrome and contribute to the progression of renal injury. The antihypertensive and anti-inflammatory actions of epoxides and soluble epoxide hydrolase inhibitors make these attractive eicosanoid therapeutic targets for chronic kidney disease in patients with cardiometabolic syndrome.
BACKGROUND: Obesity, hypertension and Type 2 diabetes are major contributing factors to the increase in the number of patients that have chronic kidney disease. The clustering of visceral obesity and cardiovascular risk factors has been designated metabolic syndrome or cardiometabolic syndrome. Cardiometabolic syndrome is associated with a complex systemic inflammatory state that has been implicated in medically important complications, including endothelial dysfunction. Inflammation, endothelial dysfunction and insulin resistance are interrelated and have reciprocal relationships that link cardiovascular and metabolic diseases. Ultimately, cardiometabolic syndrome increases the risk for cardiovascular events and end-organ damage. Although the number of patients with cardiometabolic syndrome is escalating, therapeutic approaches have not been developed that provide protection to the kidney. OBJECTIVE: The objective of this review is to provide an overview of the contribution of eicosanoids to renal damage in cardiometabolic syndrome. RESULTS/ CONCLUSION:Eicosanoids are altered in cardiometabolic syndrome and contribute to the progression of renal injury. The antihypertensive and anti-inflammatory actions of epoxides and soluble epoxide hydrolase inhibitors make these attractive eicosanoid therapeutic targets for chronic kidney disease in patients with cardiometabolic syndrome.
Authors: E T Morgan; V Ullrich; A Daiber; P Schmidt; N Takaya; H Shoun; J C McGiff; A Oyekan; C J Hanke; W B Campbell; C S Park; J S Kang; H G Yi; Y N Cha; D Mansuy; J L Boucher Journal: Drug Metab Dispos Date: 2001-11 Impact factor: 3.922
Authors: Andrea Picchi; Xue Gao; Souad Belmadani; Barry J Potter; Marta Focardi; William M Chilian; Cuihua Zhang Journal: Circ Res Date: 2006-06-01 Impact factor: 17.367
Authors: Sven Wassmann; Michaela Stumpf; Kerstin Strehlow; Andreas Schmid; Bernhard Schieffer; Michael Böhm; Georg Nickenig Journal: Circ Res Date: 2003-12-29 Impact factor: 17.367
Authors: Ahmed A Elmarakby; Jeffrey E Quigley; Jeffrey J Olearczyk; Aarthi Sridhar; Anthony K Cook; Edward W Inscho; David M Pollock; John D Imig Journal: Hypertension Date: 2007-10-15 Impact factor: 10.190
Authors: Vladimir Burmistrov; Christophe Morisseau; Kin Sing Stephen Lee; Diyala S Shihadih; Todd R Harris; Gennady M Butov; Bruce D Hammock Journal: Bioorg Med Chem Lett Date: 2014-03-20 Impact factor: 2.823
Authors: Vladimir Burmistrov; Christophe Morisseau; Vladimir D'yachenko; Dmitry Karlov; Gennady M Butov; Bruce D Hammock Journal: Bioorg Med Chem Lett Date: 2019-12-18 Impact factor: 2.823
Authors: Shailendra P Singh; Joseph Schragenheim; Jian Cao; John R Falck; Nader G Abraham; Lars Bellner Journal: Prostaglandins Other Lipid Mediat Date: 2016-07-11 Impact factor: 3.072
Authors: Vladimir Burmistrov; Christophe Morisseau; Dmitry Karlov; Dmitry Pitushkin; Andrey Vernigora; Elena Rasskazova; Gennady M Butov; Bruce D Hammock Journal: Bioorg Med Chem Lett Date: 2020-07-24 Impact factor: 2.823
Authors: Alan R Parrish; Gang Chen; Robert C Burghardt; Takaho Watanabe; Christophe Morisseau; Bruce D Hammock Journal: Cell Biol Toxicol Date: 2008-04-03 Impact factor: 6.691
Authors: John D Imig; Katie A Walsh; Md Abdul Hye Khan; Tasuku Nagasawa; Mary Cherian-Shaw; Sean M Shaw; Bruce D Hammock Journal: Exp Biol Med (Maywood) Date: 2012-12